REPL

SEC source: 0001104659-25-052145 · tm2515608-6_4seq1.xml · nonDerivative · entry 1

Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,933

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $8.05 to $8.80 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-25-052143 · tm2515608-4_4seq1.xml · nonDerivative · entry 1

Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 343,576

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $8.05 to $8.80 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-25-052142 · tm2515608-3_4seq1.xml · nonDerivative · entry 1

Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 143,522

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $8.05 to $8.79 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-25-052147 · tm2515608-7_4seq1.xml · nonDerivative · entry 1

Astley-Sparke Philip · CIK 0001376491 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,405,071

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $8.05 to $8.80 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-25-052144 · tm2515608-5_4seq1.xml · nonDerivative · entry 1

Schwendenman Andrew · CIK 0001977879 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 68,284

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $8.05 to $8.80 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-25-052140 · tm2515608-2_4seq1.xml · nonDerivative · entry 1

Sarchi Christopher · CIK 0001986597 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 128,296

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $8.05 to $8.80 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-25-031832 · tm2511407-8_4seq1.xml · derivative · entry 2

Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,500

Underlying: Common Stock · 67,500 shares

Expires 2035-04-01

F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2026, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

SEC source: 0001104659-25-031832 · tm2511407-8_4seq1.xml · nonDerivative · entry 1

Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 154,885

F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2026 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2029, subject to the Reporting Person's continuous service to the Issuer.

SEC source: 0001104659-25-031835 · tm2511407-11_4seq1.xml · derivative · entry 2

Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2035-04-01

F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2026, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

SEC source: 0001104659-25-031835 · tm2511407-11_4seq1.xml · nonDerivative · entry 1

Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 368,681

F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2026 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2029, subject to the Reporting Person's continuous service to the Issuer.

SEC source: 0001104659-25-031829 · tm2511407-5_4seq1.xml · derivative · entry 2

Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,500

Underlying: Common Stock · 67,500 shares

Expires 2035-04-01

F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2026, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

SEC source: 0001104659-25-031829 · tm2511407-5_4seq1.xml · nonDerivative · entry 1

Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,057

F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2026 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2029, subject to the Reporting Person's continuous service to the Issuer.

SEC source: 0001104659-25-031828 · tm2511407-4_4seq1.xml · derivative · entry 1

Weinand Dieter · CIK 0001744419 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2035-04-01

F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2026.

SEC source: 0001104659-25-031831 · tm2511407-7_4seq1.xml · derivative · entry 1

Dhingra Kapil · CIK 0001456849 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2035-04-01

F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2026.

SEC source: 0001104659-25-031834 · tm2511407-10_4seq1.xml · derivative · entry 1

Pucci Paolo · CIK 0001436861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2035-04-01

F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2026.

SEC source: 0001104659-25-031830 · tm2511407-6_4seq1.xml · derivative · entry 1

SLATTERY JOSEPH P · CIK 0001246530 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2035-04-01

F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2026.

SEC source: 0001104659-25-031833 · tm2511407-9_4seq1.xml · derivative · entry 1

Balachandran Madhavan · CIK 0001555508 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2035-04-01

F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2026.

SEC source: 0001104659-25-031836 · tm2511407-12_4seq1.xml · derivative · entry 1

Peeples-Dyer Veleka · CIK 0001978705 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2035-04-01

F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2026.

SEC source: 0001104659-25-031826 · tm2511407-3_4seq1.xml · derivative · entry 2

Sarchi Christopher · CIK 0001986597 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,500

Underlying: Common Stock · 67,500 shares

Expires 2035-04-01

F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2026, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

SEC source: 0001104659-25-031826 · tm2511407-3_4seq1.xml · nonDerivative · entry 1

Sarchi Christopher · CIK 0001986597 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 132,045

F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2026 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2029, subject to the Reporting Person's continuous service to the Issuer.

SEC source: 0001104659-25-031825 · tm2511407-2_4seq1.xml · derivative · entry 1

Oliger Christy J. · CIK 0001822092 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2035-04-01

F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2026.

SEC source: 0001104659-25-031823 · tm2511407-1_4seq1.xml · derivative · entry 2

Schwendenman Andrew · CIK 0001977879 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2035-04-01

F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2026, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

SEC source: 0001104659-25-031823 · tm2511407-1_4seq1.xml · nonDerivative · entry 1

Schwendenman Andrew · CIK 0001977879 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,571

F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2026 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2029, subject to the Reporting Person's continuous service to the Issuer.

SEC source: 0000950170-25-035633 · ownership.xml · derivative · entry 2

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 64,000

Underlying: Common Stock · 64,000 shares

Expires 2035-03-05

F1 · shares: 64,000 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Replimune Group, Inc. (the "Issuer") granted by the Issuer to Michael Goller, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on March 5, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Omnibus Incentive Compensation Plan ("Incentive Plan"). The Stock Options have a strike price of $12.29 per share, 25% of which vest on March 5, 2026 with the remaining 75% vesting in 24 equal monthly installments thereafter, subject to Michael Goller's continued service on the board of directors of the Issuer (the "Board") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on March 5, 2035.

F1 · derivative.exercise_date: 64,000 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Replimune Group, Inc. (the "Issuer") granted by the Issuer to Michael Goller, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on March 5, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Omnibus Incentive Compensation Plan ("Incentive Plan"). The Stock Options have a strike price of $12.29 per share, 25% of which vest on March 5, 2026 with the remaining 75% vesting in 24 equal monthly installments thereafter, subject to Michael Goller's continued service on the board of directors of the Issuer (the "Board") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on March 5, 2035.

F1 · derivative.underlying: 64,000 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Replimune Group, Inc. (the "Issuer") granted by the Issuer to Michael Goller, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on March 5, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Omnibus Incentive Compensation Plan ("Incentive Plan"). The Stock Options have a strike price of $12.29 per share, 25% of which vest on March 5, 2026 with the remaining 75% vesting in 24 equal monthly installments thereafter, subject to Michael Goller's continued service on the board of directors of the Issuer (the "Board") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on March 5, 2035.

F2 · ownership.nature: Michael Goller serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F6 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options.

F7 · ownership.nature: The acquisition of Stock Options reported on this form represents a single grant to Michael Goller of 64,000 Stock Options on Table II. This grant of 64,000 Stock Options for Michael Goller is reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F9 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0000950170-25-035633 · ownership.xml · derivative · entry 1

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director · 10% owner

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director · 10% owner

667, L.P. · CIK 0001551139 · Director · 10% owner

Baker Brothers Life Sciences LP · CIK 0001363364 · Director · 10% owner

BAKER FELIX · CIK 0001087940 · Director · 10% owner

BAKER JULIAN · CIK 0001087939 · Director · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 64,000

Underlying: Common Stock · 64,000 shares

Expires 2035-03-05

F1 · shares: 64,000 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Replimune Group, Inc. (the "Issuer") granted by the Issuer to Michael Goller, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on March 5, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Omnibus Incentive Compensation Plan ("Incentive Plan"). The Stock Options have a strike price of $12.29 per share, 25% of which vest on March 5, 2026 with the remaining 75% vesting in 24 equal monthly installments thereafter, subject to Michael Goller's continued service on the board of directors of the Issuer (the "Board") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on March 5, 2035.

F1 · derivative.exercise_date: 64,000 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Replimune Group, Inc. (the "Issuer") granted by the Issuer to Michael Goller, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on March 5, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Omnibus Incentive Compensation Plan ("Incentive Plan"). The Stock Options have a strike price of $12.29 per share, 25% of which vest on March 5, 2026 with the remaining 75% vesting in 24 equal monthly installments thereafter, subject to Michael Goller's continued service on the board of directors of the Issuer (the "Board") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on March 5, 2035.

F1 · derivative.underlying: 64,000 non-qualified stock options ("Stock Options") exercisable solely into common stock ("Common Stock") of Replimune Group, Inc. (the "Issuer") granted by the Issuer to Michael Goller, a full-time employee of Baker Bros. Advisors LP (the "Adviser"), on March 5, 2025, in his capacity as a director of the Issuer, pursuant to the Issuer's 2018 Omnibus Incentive Compensation Plan ("Incentive Plan"). The Stock Options have a strike price of $12.29 per share, 25% of which vest on March 5, 2026 with the remaining 75% vesting in 24 equal monthly installments thereafter, subject to Michael Goller's continued service on the board of directors of the Issuer (the "Board") through the vesting date or an earlier change in control of the Issuer. The Stock Options expire on March 5, 2035.

F2 · ownership.nature: Michael Goller serves on the Board as a representative of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds") and their affiliates and control persons.

F3 · ownership.nature: Baker Bros. Advisors LP (the "Adviser") serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held for the benefit of the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held for the benefit of the Funds.

F4 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Michael Goller does not have a right to any of the Issuer's securities issued as compensation for his service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in such securities. The Funds each own an indirect proportionate pecuniary interest in such securities. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the shares of Common Stock, Stock Options and Common Stock issued upon exercise of Stock Options (i.e. no direct pecuniary interest) issued as compensation for such Board service.

F6 · ownership.nature: Pursuant to the policies of the Adviser, the Adviser has voting and dispositive power over the Stock Options and any Common Stock received as a result of the exercise of Stock Options.

F7 · ownership.nature: The acquisition of Stock Options reported on this form represents a single grant to Michael Goller of 64,000 Stock Options on Table II. This grant of 64,000 Stock Options for Michael Goller is reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F8 · ownership.nature: After giving effect to the transaction reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in the Stock Options reported in column 9 of Table II held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

SEC source: 0001104659-24-129864 · tm2431484-1_4seq1.xml · nonDerivative · entry 1

Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 202,014

F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on April 3, 2024, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.20 to $12.62. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 202,014 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 513,750 shares of the Issuer's common stock, 189,478 of which are exercisable as of the date hereof.

SEC source: 0001104659-24-121188 · tm2429047-2_4seq1.xml · nonDerivative · entry 1

Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,885

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

SEC source: 0001104659-24-121187 · tm2429047-1_4seq1.xml · nonDerivative · entry 1

Sarchi Christopher · CIK 0001986597 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 87,045

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

SEC source: 0001104659-24-097495 · tm2423447-2_4seq1.xml · derivative · entry 1

Balachandran Madhavan · CIK 0001555508 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,000

Underlying: Common Stock · 64,000 shares

Expires 2034-09-04

F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on September 4, 2025, and the remainder of the shares underlying this stock option vest in 24 approximately equal monthly installments thereafter.

SEC source: 0001104659-24-095834 · tm2423182-1_4seq1.xml · nonDerivative · entry 1

Astley-Sparke Philip · CIK 0001376491 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,437,350

SEC source: 0001104659-24-090980 · tm2422092-1_4seq1.xml · nonDerivative · entry 1

Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 101,057

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $10.18 to $10.20 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-24-070108 · tm2416882-1_4seq1.xml · nonDerivative · entry 1

Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 117,131

F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on February 13, 2024, that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended.

F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.50 to $7.55. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.

F3 · balance_after: Following the sales reported on this Form 4, the reporting person continues to beneficially own 117,131 shares of the Issuer's common stock, including restricted stock units. The reporting person also holds options to acquire an aggregate of 266,750 shares of the Issuer's common stock, 84,280 of which are exercisable as of the date hereof.

SEC source: 0001104659-24-063558 · tm2414961-1_4seq1.xml · nonDerivative · entry 1

Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 133,012

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-24-063559 · tm2414961-2_4seq1.xml · nonDerivative · entry 1

Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 212,014

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-24-063561 · tm2414961-4_4seq1.xml · nonDerivative · entry 1

Astley-Sparke Philip · CIK 0001376491 · Director · Executive Chairman

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,487,350

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.55 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-24-063562 · tm2414961-5_4seq1.xml · nonDerivative · entry 1

Love Colin · CIK 0001376493 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 777,345

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-24-063560 · tm2414961-3_4seq1.xml · nonDerivative · entry 1

Coffin Robert · CIK 0001376492 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,821,872

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-24-063563 · tm2414961-6_4seq1.xml · nonDerivative · entry 1

Schwendenman Andrew · CIK 0001977879 · Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,238

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.56 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-24-063564 · tm2414961-7_4seq1.xml · nonDerivative · entry 1

Sarchi Christopher · CIK 0001986597 · Chief Commercial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 92,252

F1 · shares: Represents shares of the Issuer's common stock (the "Shares") sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreements under which the RSUs were granted and does not represent a discretionary sale by the Reporting Person.

F2 · price: The price reported reflects a weighted average price of the Shares. The Shares were sold in multiple transactions at prices ranging from $6.46 to $6.55 per Share. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the Securities Exchange Commission staff, upon request, information regarding the number of Shares sold at each price within the range.

SEC source: 0001104659-24-043256 · tm2410652-9_4seq1.xml · derivative · entry 2

Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2034-04-01

F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2025, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

SEC source: 0001104659-24-043256 · tm2410652-9_4seq1.xml · nonDerivative · entry 1

Xynos Konstantinos · CIK 0001956241 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,379

F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2025 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2028, subject to the Reporting Person's continuous service to the Issuer.

SEC source: 0001104659-24-043258 · tm2410652-11_4seq1.xml · derivative · entry 2

Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250,000

Underlying: Common Stock · 250,000 shares

Expires 2034-04-01

F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2025, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

SEC source: 0001104659-24-043258 · tm2410652-11_4seq1.xml · nonDerivative · entry 1

Patel Sushil · CIK 0001860609 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 232,208

F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2025 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2028, subject to the Reporting Person's continuous service to the Issuer.

SEC source: 0001104659-24-043253 · tm2410652-5_4seq1.xml · derivative · entry 2

Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 80,000

Underlying: Common Stock · 80,000 shares

Expires 2034-04-01

F2 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2025, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter.

SEC source: 0001104659-24-043253 · tm2410652-5_4seq1.xml · nonDerivative · entry 1

Hill Emily Luisa · CIK 0001778279 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 109,995

F1 · shares: Represents shares of the Issuer's common stock issuable upon settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on May 15, 2025 and the remainder will vest in three approximately equal annual installments thereafter until May 15, 2028, subject to the Reporting Person's continuous service to the Issuer.

SEC source: 0001104659-24-043251 · tm2410652-4_4seq1.xml · derivative · entry 1

Weinand Dieter · CIK 0001744419 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-04-01

F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2025.

SEC source: 0001104659-24-043255 · tm2410652-8_4seq1.xml · derivative · entry 1

Dhingra Kapil · CIK 0001456849 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-04-01

F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2025.

SEC source: 0001104659-24-043257 · tm2410652-10_4seq1.xml · derivative · entry 1

Pucci Paolo · CIK 0001436861 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-04-01

F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2025.

SEC source: 0001104659-24-043252 · tm2410652-7_4seq1.xml · derivative · entry 1

SLATTERY JOSEPH P · CIK 0001246530 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-04-01

F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2025.

SEC source: 0001104659-24-043247 · tm2410652-6_4seq1.xml · derivative · entry 1

Levitsky Hyam · CIK 0001375792 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2034-04-01

F1 · derivative.exercise_date: The shares underlying this option vest entirely on April 1, 2025.